NLRP9 and thyroid cancer: Considering the overall incidence rate of thyroid cancer is approximately 11.95 × 10−5 among different countries [34], with FNMTC accounting for about 5% of NMTC, we excluded variants (DUSP16, CHD4, SSPO, NLRP9, ANO2, CTBS, OR51B4) from the general population with allele frequencies higher than 0.001 based on the 1000 Genomes Project and ExAC databases.